Informations

As 2024 concludes, the year has left us with significant milestones and breakthroughs in oncology. Oncology Frontier invited Dr. Yongmei Yin from Jiangsu Cancer Hospital to summarize the year’s advancements in HER2-positive breast cancer research, highlighting the clinical transformations brought by innovative therapies.

Oncology Frontier: With the progress in the precise diagnosis of lung cancer, many rare/rare gene mutations have been discovered. First, could you briefly introduce the current hottest rare targets? Dr.…

Pancreatic cancer (PC) stands as one of the most lethal cancers globally, ranking 12th in prevalence and sixth in cancer-related deaths. Its aggressive nature and often late diagnosis contribute to a dismal 5-year survival rate of merely 12%. While surgical resection offers the only potential cure, most patients are diagnosed at advanced stages, rendering surgery…

At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the “New Little Red Book”) was officially released during the 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee. This updated edition provides fresh guidance for…

Oncology Frontier: Perioperative treatment for early-stage non-small cell lung cancer (NSCLC) has entered the era of targeted and immunotherapy. What breakthroughs in perioperative targeted therapy were seen in 2024? Dr.…

In recent years, as research has deepened, the exploration of gastric cancer’s molecular mechanisms has gradually shifted from histological classification to molecular classification. Different biomarkers have profoundly influenced the treatment landscape of advanced gastric cancer in first-line and subsequent therapies. At the close of this year, Oncology Frontier  is honored to invite Dr. Ai Li…

The “Northern Breast Cancer Salon Annual Progress Review” was held from January 3–5, 2025, in Beijing. The conference comprehensively reviewed the latest advances in breast cancer diagnosis, treatment, and research over the past year, delving into the latest findings for various breast cancer subtypes and their impact on clinical practice. The conference also focused on…

Oncology Frontier: Could you briefly introduce the key advancements in the treatment of advanced triple-negative breast cancer (TNBC) in 2024? How have these advancements impacted patients’ survival or quality of…